Ten‐year outcomes in a randomized phase II study of kidney transplant recipients administered belatacept 4‐weekly or 8‐weekly

    loading  Checking for direct PDF access through Ovid

Abstract

Abstract unavailable for this article.

    loading  Loading Related Articles